| Similar Articles |
|---|
 |
Chemistry World
August 15, 2012 |
The latent threat of tuberculosis Although TB was close to being eradicated in the developed world, it is a major problem in developing countries. With drug-resistant strains on the increase, Clare Sansom outlines the latest in the fight against this killer disease   |
Pharmaceutical Executive
September 1, 2011 |
Filling Front and Center in the Fight against TB Dr. Mel Spigelman, President and CEO of the TB Alliance, discusses the organization's priorities in developing treatments for tuberculosis. |
Pharmaceutical Executive
September 1, 2011 |
The Power of PDP Can cooperative ties between Big Pharma, NGOs, government, and international organizations pay the freight in making the fight against neglected diseases a permanent fix in global health? |
Pharmaceutical Executive
November 1, 2014
Casey McDonald |
Advocacy Beat: Progress in Global Access to TB Drugs Treatment Action Group reaches a milestone in improving access to much-needed treatments for tuberculosis. |
Pharmaceutical Executive
September 1, 2006
Kieran Hartsough |
Benchmarking AIDS Pharma is taking on the global AIDS crisis. But who has crafted the best approach? The Interfaith Center on Corporate Responsibility defines best practices and matches major companies head-to-head. Grades are posted inside. |
Bio-IT World
Dec 2005/Jan 2006
Salvatore Salamone |
Gates, Clinton Address Global Health Summit The conference brought together leaders in business, government, medicine, public philanthropic groups, and the arts to address and develop solutions to the world's heath crises. |
Pharmaceutical Executive
September 1, 2006
Jill Wechsler |
Washington Report: New Partnerships Pursue Old Diseases A new wave of collaborations between industry, non-profits, and government seeks affordable treatments for neglected diseases around the world. |
Pharmaceutical Executive
October 1, 2005
Jill Wechsler |
Washington Report: Antivirals: Meeting a World of Need The international fight against AIDS requires drugs -- and policy. |
BusinessWeek
August 26, 2010
Tom Randall |
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA |
Chemistry World
January 3, 2013
Andrew Turley |
TB drug milestone for bedaquiline Bedaquiline (sirturo) has become the first drug to be approved in the US for the treatment of multi-drug resistant tuberculosis |
Chemistry World
July 2010
Anna Lewcock |
Medicine made to measure Healthcare tailored to suit the genetic makeup of the patient is finally coming to fruition. |
Wired
July 24, 2007
Thomas Goetz |
The Ultimate Diagnostic Device (By the Way, You've Got Drug-Resistant TB!) The CDC's goal of a tuberculosis-free society grew short due to the development of drug-resistant strains. But new standards for detection are in the works. |
Pharmaceutical Executive
August 1, 2013
Joseph Saba |
New Rules for a New Africa Declining revenue growth in the United States and Europe have sent pharmaceutical companies in search of opportunities in the BRICs and other emerging economies. Now, companies are finally turning their attention to Africa. |
Pharmaceutical Executive
December 1, 2010
Zhu Shen |
China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda |
Pharmaceutical Executive
January 1, 2011 |
The Steep, Slow Climb A survey of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade. |
Pharmaceutical Executive
October 1, 2011
William Looney |
Partnering with the New Players Carlos Morel has been closely associated with the Oswaldo Cruz Foundation from the start of his career and now holds a pivotal role in creating a new infrastructure to support translational research on diseases critical to Brazil and other emerging country markets. |
AboutSafety
September 11, 2001 |
Tuberculosis (TB) TB is a potentially severe contagious disease that is spread from person to person via the air. The TB germs may spray into the air if a person with TB disease of the lungs or throat coughs, speaks or sneezes... |
Chemistry World
March 27, 2013
Eugene Gerden |
Russian investment vehicle sets sights on innovative drugs Russian state-owned nanotechnology giant Rusnano is hoping to break into the pharmaceutical sector with sizeable investments in firms seeking to produce innovative drugs. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
Salon.com
May 18, 2000
Sabin Russell |
The dream and the coming disaster AIDS threatens to ravage the hopes of South Africa's young democracy. Don't expect leaders to get excited because a few companies cut the cost of HIV drugs. |
BusinessWeek
August 5, 2010
Bennett & Randall |
AIDS Drugs Flow to the Third World Drugmakers, once blasted for their practices, are slashing prices and licensing AIDS drugs for free to nonprofits or local manufacturers in developing countries. |
Pharmaceutical Executive
December 1, 2005
Ron Feemster |
The PharmExec 2005 Pipeline Report Dry? Not quite. Instead of 1990s-style blockbusters, pharma's new molecules are niche drugs, cancer treatments and -- at last -- innovative mechanisms for troublesome targets: Acomplia [rimonabant] by Sanofi-Aventis... AMG 162 [denosumab] by Amgen... etc. |
Chemistry World
May 31, 2013
Phillip Broadwith |
Japanese pharma opens compound vaults Japanese pharmaceutical companies are opening up their libraries of experimental compound as part of a new partnership program. The initiative aims to find new drugs for malaria, tuberculosis and neglected tropical diseases. |
Pharmaceutical Executive
May 1, 2007
Waseem Noor |
Toolkit: How To Be a Better Partner Big pharmas and little biotechs have been getting hitched for years. Now it's time to add a little innovation to the relationship. Three new rules will keep the game exciting. |
The Motley Fool
August 10, 2010
Ryan McBride |
Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive. |
Chemistry World
October 8, 2010
Sarah Houlton |
U-turn on Alzheimer's drugs in the UK The UK National Institute for Health and Clinical Excellence proposes that those with mild disease will be able to receive them from early next year, on the basis of growing clinical evidence of their effectiveness. |
Scientific American
February 2009
John Rennie |
Tuberculosis, The Unromantic Killer Tuberculosis has never stopped being one of the world's most lethal infections |
Pharmaceutical Executive
January 1, 2012
Jill Wechsler |
New Year, New Issues Look for action in 2012 on drug access, shortages, innovation, and transparency. The 800-pound gorilla in the room is the looming Supreme Court decision on the constitutionality of the Obama health reform legislation. |
Salon.com
June 1, 2001
Daryl Lindsey |
The AIDS-drug warrior Outspoken AIDS-drug activist Jamie Love says pharmaceutical companies must be forced to yield their patents to save hundreds of thousands of lives. Is he a visionary -- or a dangerous radical? |
HHMI Bulletin
Aug 2010 |
Bishai Named Director of K-RITH A prominent tuberculosis researcher and doctor will become the first permanent director of the KwaZulu-Natal Research Institute for Tuberculosis and HIV. |
The Motley Fool
March 31, 2011
Brian Orelli |
Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones? |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
Pharmaceutical Executive
August 1, 2012 |
Sunny Outlook for Biopharm 2020? Albert Wertheimer looks beyond today's dark clouds with a comparatively sunny forecast for the biopharm industry in 2020. Just watch out for the harsh light of complacency. |
Pharmaceutical Executive
October 1, 2011
Jill Wechsler |
At the Helm of Industry As the lead FDA official overseeing the testing and approval of new drugs and biotech therapies for some 20 years, Dr. Janet Woodcock has built a robust and modern drug regulatory system. |
Salon.com
May 1, 2001
Daryl Lindsey |
Amy and Goliath A first-year law student brought a giant pharmaceutical to its knees. But will her victory for South Africa's AIDS sufferers deprive the world of new medicines? |
Salon.com
June 27, 2001
Daryl Lindsey |
A pandemic fueled by poverty A doctor says the fight to get cheap AIDS drugs to Africa is misguided: These people need water, food and basic healthcare... |
Pharmaceutical Executive
June 1, 2014
Jill Wechsler |
What Price Innovation? Payers, drug plans seek clear assessment of drug value to rationalize high drug prices. |
Pharmaceutical Executive
April 1, 2012
Feam & Lagus |
Providing Access Now While regulatory frameworks and medical practices differ between countries, many patients still need early access to new drugs. Industry can help. |
Pharmaceutical Executive
January 1, 2014
Jill Wechsler |
Pharma Challenges for 2014 Pricing and personalized medicine are key themes shaping drug development and marketing |
The Motley Fool
June 9, 2010
Brian Orelli |
ASCO Pops and Drops Themes and company news from the annual meeting of the American Society of Clinical Oncology. |
Salon.com
March 19, 2001
Ben Barber |
Fighting the plague The World Trade Organization steps into Africa's AIDS crisis, creating incentives for pharmaceutical companies to give some of their drugs away. |
Nursing
June 2010
Daniel A. Hussar |
New drugs 2010, part 2 In this article, you'll learn about 14 recently marketed new drugs. |
Pharmaceutical Executive
July 1, 2013
Jill Wechsler |
Seeking Supply Chain Security FDA wants pharma leaders to do more to ensure drug quality at home and abroad. |
Nursing
June 2011
Daniel A. Hussar |
New Drugs 2011: Part 2 In this article, you'll learn about seven recently approved drugs, including: fingolimod hydrochloride, an oral drug indicated to treat patients with relapsing forms of multiple sclerosis. |
Pharmaceutical Executive
June 1, 2014
O'Connor et al. |
Challenges to the Specialty Business Model New constraints require new solutions. Innovative, value-based pricing models will be critical to securing reimbursement and continued market access of high-price drugs. |
Salon.com
July 13, 2000
Megan Williams |
African mothers: Save us, too AIDS activists say providing drugs to prevent HIV transmission to babies but not treating their mothers is unconscionable. |
Pharmaceutical Executive
September 1, 2010 |
Explaining the Drug Drought Industry needs to engage in a broader public debate on ways to rekindle the innovative engine in new drug discovery and development. |
Pharmaceutical Executive
November 1, 2014
Jill Wechsler |
Outrage Grows Over Drug Pricing Insurers, physicians attack high-cost therapies in anticipation of specialty drug surge. |
The Motley Fool
May 28, 2010
Brian Orelli |
Innovators Will Rule the Economic Crisis Roche's CEO says two areas of health care can prosper. I agree. |
